JP2011500851A5 - - Google Patents

Download PDF

Info

Publication number
JP2011500851A5
JP2011500851A5 JP2010531299A JP2010531299A JP2011500851A5 JP 2011500851 A5 JP2011500851 A5 JP 2011500851A5 JP 2010531299 A JP2010531299 A JP 2010531299A JP 2010531299 A JP2010531299 A JP 2010531299A JP 2011500851 A5 JP2011500851 A5 JP 2011500851A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
composition according
patient
active agent
dry powder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2010531299A
Other languages
English (en)
Japanese (ja)
Other versions
JP2011500851A (ja
JP5813323B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/081221 external-priority patent/WO2009055742A2/en
Publication of JP2011500851A publication Critical patent/JP2011500851A/ja
Publication of JP2011500851A5 publication Critical patent/JP2011500851A5/ja
Application granted granted Critical
Publication of JP5813323B2 publication Critical patent/JP5813323B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2010531299A 2007-10-24 2008-10-24 活性薬剤の送達方法 Active JP5813323B2 (ja)

Applications Claiming Priority (13)

Application Number Priority Date Filing Date Title
US98236807P 2007-10-24 2007-10-24
US60/982,368 2007-10-24
US98562007P 2007-11-05 2007-11-05
US60/985,620 2007-11-05
US2227408P 2008-01-18 2008-01-18
US61/022,274 2008-01-18
US3374008P 2008-03-04 2008-03-04
US61/033,740 2008-03-04
US5212708P 2008-05-09 2008-05-09
US61/052,127 2008-05-09
US9482308P 2008-09-05 2008-09-05
US61/094,823 2008-09-05
PCT/US2008/081221 WO2009055742A2 (en) 2007-10-24 2008-10-24 Delivery of active agents

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015145109A Division JP2015227357A (ja) 2007-10-24 2015-07-22 活性薬剤の送達方法

Publications (3)

Publication Number Publication Date
JP2011500851A JP2011500851A (ja) 2011-01-06
JP2011500851A5 true JP2011500851A5 (https=) 2011-12-08
JP5813323B2 JP5813323B2 (ja) 2015-11-17

Family

ID=40545981

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2010531299A Active JP5813323B2 (ja) 2007-10-24 2008-10-24 活性薬剤の送達方法
JP2015145109A Pending JP2015227357A (ja) 2007-10-24 2015-07-22 活性薬剤の送達方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015145109A Pending JP2015227357A (ja) 2007-10-24 2015-07-22 活性薬剤の送達方法

Country Status (11)

Country Link
US (6) US8372804B2 (https=)
EP (1) EP2214647A2 (https=)
JP (2) JP5813323B2 (https=)
KR (2) KR20100090692A (https=)
CN (1) CN101969928B (https=)
AU (1) AU2008316636B2 (https=)
BR (1) BRPI0818874A2 (https=)
CA (1) CA2703234C (https=)
MX (1) MX2010004508A (https=)
RU (2) RU2467741C2 (https=)
WO (1) WO2009055742A2 (https=)

Families Citing this family (55)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9006175B2 (en) 1999-06-29 2015-04-14 Mannkind Corporation Potentiation of glucose elimination
ES2569916T3 (es) 1999-06-29 2016-05-13 Mannkind Corporation Formulaciones farmacéuticas que comprenden insulina complejada con una dicetopiperazina
US6923175B2 (en) 2002-03-20 2005-08-02 Mannkind Corporation Inhalation apparatus
US8921311B2 (en) 2003-08-01 2014-12-30 Mannkind Corporation Method for treating hyperglycemia
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
MX373000B (es) 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
EP1986679B1 (en) 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
JP5813323B2 (ja) * 2007-10-24 2015-11-17 マンカインド コーポレイション 活性薬剤の送達方法
US8785396B2 (en) 2007-10-24 2014-07-22 Mannkind Corporation Method and composition for treating migraines
EP2211842B1 (en) * 2007-10-24 2015-08-12 MannKind Corporation An inhalable dry powder formulation comprising glp-1 for use in the treatment of hyperglycemia and diabetes by pulmonary administration
CN101827626B (zh) 2008-06-13 2015-03-18 曼金德公司 干粉吸入器和用于药物输送的系统
US8485180B2 (en) 2008-06-13 2013-07-16 Mannkind Corporation Dry powder drug delivery system
ES2421385T3 (es) 2008-06-20 2013-09-02 Mannkind Corp Aparato interactivo y procedimiento para establecer el perfil, en tiempo real, de esfuerzos de inhalación
TWI532497B (zh) 2008-08-11 2016-05-11 曼凱公司 超快起作用胰島素之用途
US8314106B2 (en) 2008-12-29 2012-11-20 Mannkind Corporation Substituted diketopiperazine analogs for use as drug delivery agents
US20100169260A1 (en) * 2008-12-30 2010-07-01 Searete Llc Methods and systems for presenting an inhalation experience
US9750903B2 (en) 2008-12-30 2017-09-05 Gearbox, Llc Method for administering an inhalable compound
DK2379100T3 (en) 2009-01-08 2014-12-01 Mannkind Corp Treatment of hyperglycemia with GLP-1
DK2405963T3 (da) 2009-03-11 2013-12-16 Mannkind Corp Apparat, system og fremgangsmåde til at måle modstand i en inhalator
KR102584844B1 (ko) * 2009-06-12 2023-10-04 맨카인드 코포레이션 한정된 비표면적을 갖는 디케토피페라진 마이크로입자
EP3556356B1 (en) * 2009-06-12 2021-05-05 MannKind Corporation Diketopiperazine microparticles with defined isomer content
WO2011053963A1 (en) * 2009-11-02 2011-05-05 Mannkind Corporation Reactor for producing pharmaceutical particles in a precipitation process
EP2496253B1 (en) 2009-11-02 2019-01-09 MannKind Corporation Apparatus and method for cryogranulating a pharmaceutical composition
AU2015201885B2 (en) * 2009-11-02 2017-04-20 Mannkind Corporation Apparatus and method for cryogranulating a pharmaceutical composition
CA2778698A1 (en) 2009-11-03 2011-05-12 Mannkind Corporation An apparatus and method for simulating inhalation efforts
US8790704B2 (en) * 2010-06-10 2014-07-29 Monosol Rx, Llc Combination peptide-nanoparticles and delivery systems incorporating same
CN102985125A (zh) 2010-06-21 2013-03-20 曼金德公司 干粉药物输送系统和方法
AU2015249177B2 (en) * 2010-11-09 2017-08-03 Mannkind Corporation Composition comprising a serotonin receptor agonist and a diketopiperazine for treating migraines
MX340112B (es) * 2010-11-09 2016-06-27 Mannkind Corp Composicion que comprende un agonista de receptor de serotonina y una dicetopiperazina para el tratamiento de migrañas.
SG194034A1 (en) 2011-04-01 2013-11-29 Mannkind Corp Blister package for pharmaceutical cartridges
WO2012174472A1 (en) 2011-06-17 2012-12-20 Mannkind Corporation High capacity diketopiperazine microparticles
MX2014004983A (es) 2011-10-24 2014-09-22 Mannkid Corp Metodos y composiciones para tratar dolor.
KR102264177B1 (ko) 2012-07-12 2021-06-11 맨카인드 코포레이션 건조 분말 약물 전달 시스템 및 방법
US20150231067A1 (en) * 2012-08-29 2015-08-20 Mannkind Corporation Method and composition for treating hyperglycemia
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
WO2014066856A1 (en) 2012-10-26 2014-05-01 Mannkind Corporation Inhalable influenza vaccine compositions and methods
HK1211232A1 (en) 2012-12-21 2016-05-20 Sanofi Exendin-4 derivatives as dual glp1/gip or trigonal glp1/gip/glucagon agonists
EP3587404B1 (en) * 2013-03-15 2022-07-13 MannKind Corporation Microcrystalline diketopiperazine compositions, methods for preparation and use thereof
MX375448B (es) * 2013-07-18 2025-03-06 Mannkind Corp Composiciones farmacéuticas en polvo seco estables al calor y métodos.
EP3030294B1 (en) 2013-08-05 2020-10-07 MannKind Corporation Insufflation apparatus
WO2015086733A1 (en) 2013-12-13 2015-06-18 Sanofi Dual glp-1/glucagon receptor agonists
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重glp-1/gip受體促效劑
WO2015086728A1 (en) 2013-12-13 2015-06-18 Sanofi Exendin-4 peptide analogues as dual glp-1/gip receptor agonists
EP3080152A1 (en) 2013-12-13 2016-10-19 Sanofi Non-acylated exendin-4 peptide analogues
US10307464B2 (en) 2014-03-28 2019-06-04 Mannkind Corporation Use of ultrarapid acting insulin
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重glp-1/昇糖素受體激動劑之艾塞那肽-4衍生物
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自exendin-4之雙重glp-1/升糖素受體促效劑
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽-4(Exendin-4)之肽類雙重GLP-1/升糖素受體促效劑
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
US10561806B2 (en) 2014-10-02 2020-02-18 Mannkind Corporation Mouthpiece cover for an inhaler
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
AR105284A1 (es) 2015-07-10 2017-09-20 Sanofi Sa Derivados de exendina-4 como agonistas peptídicos duales específicos de los receptores de glp-1 / glucagón
WO2017132601A1 (en) * 2016-01-29 2017-08-03 Mannkind Corporation Dry powder inhaler
KR20250152464A (ko) * 2024-04-16 2025-10-23 한미약품 주식회사 흡입제 조성물

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4356167A (en) * 1978-01-27 1982-10-26 Sandoz, Inc. Liposome drug delivery systems
US4483922A (en) * 1982-05-14 1984-11-20 Amf Inc. Inactivation of enzymes
US4581020A (en) * 1983-07-18 1986-04-08 Trimedyne, Inc. Medication delivery device and system for percutaneous administration of medication
US4849227A (en) 1986-03-21 1989-07-18 Eurasiam Laboratories, Inc. Pharmaceutical compositions
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US6331318B1 (en) 1994-09-30 2001-12-18 Emisphere Technologies Inc. Carbon-substituted diketopiperazine delivery systems
US5693338A (en) 1994-09-29 1997-12-02 Emisphere Technologies, Inc. Diketopiperazine-based delivery systems
US5352461A (en) 1992-03-11 1994-10-04 Pharmaceutical Discovery Corporation Self assembling diketopiperazine drug delivery system
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
US6024090A (en) 1993-01-29 2000-02-15 Aradigm Corporation Method of treating a diabetic patient by aerosolized administration of insulin lispro
US5424286A (en) 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5877174A (en) 1994-12-01 1999-03-02 Toyama Chemical Co., Ltd. 2,3-diketopiperazine derivatives or their salts
US6428771B1 (en) 1995-05-15 2002-08-06 Pharmaceutical Discovery Corporation Method for drug delivery to the pulmonary system
US6006753A (en) 1996-08-30 1999-12-28 Eli Lilly And Company Use of GLP-1 or analogs to abolish catabolic changes after surgery
US6277819B1 (en) 1996-08-30 2001-08-21 Eli Lilly And Company Use of GLP-1 or analogs in treatment of myocardial infarction
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
JP2001504105A (ja) 1996-11-12 2001-03-27 ノボ ノルディスク アクティーゼルスカブ Glp―1ペプチドの利用
JP2001525371A (ja) 1997-12-05 2001-12-11 イーライ・リリー・アンド・カンパニー Glp−1製剤
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
CA2228182C (en) * 1998-01-26 2007-03-20 George Volgyesi Breath-powered mist inhaler
SE9802080D0 (sv) 1998-06-11 1998-06-11 Hellstroem Pharmaceutical composition for the treatment of functional dyspepsia and/or irritable bowel syndrome and new use of substances therein
US6720407B1 (en) 1998-08-28 2004-04-13 Eli Lilly And Company Method for administering insulinotropic peptides
ES2261195T3 (es) 1999-04-05 2006-11-16 Mannkind Corporation Metodo de formacion de particulas finas.
USRE40876E1 (en) 1999-06-21 2009-08-18 Eli Lilly And Company Method for treating non-insulin dependent diabetes using thiazolidinediones with glucagonlike peptide-1 and agonists thereof
ES2569916T3 (es) * 1999-06-29 2016-05-13 Mannkind Corporation Formulaciones farmacéuticas que comprenden insulina complejada con una dicetopiperazina
US7305986B1 (en) 1999-07-23 2007-12-11 Mannkind Corporation Unit dose capsules for use in a dry powder inhaler
US7464706B2 (en) 1999-07-23 2008-12-16 Mannkind Corporation Unit dose cartridge and dry powder inhaler
US7022674B2 (en) 1999-12-16 2006-04-04 Eli Lilly And Company Polypeptide compositions with improved stability
US6608038B2 (en) 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
ATE424413T1 (de) 2000-06-16 2009-03-15 Lilly Co Eli Analoge des glucagon-ähnlichen peptids-1
WO2002011676A2 (en) 2000-08-04 2002-02-14 Dmi Biosciences, Inc. Method of using diketopiperazines and composition containing them
US7259233B2 (en) * 2000-12-13 2007-08-21 Eli Lilly And Company Chronic treatment regimen using glucagon-like insulinotropic peptides
US7232897B2 (en) 2001-04-24 2007-06-19 Harvard University, President And Fellows Of Harvard College Compositions and methods for modulating NH2-terminal Jun Kinase activity
US7144863B2 (en) 2001-06-01 2006-12-05 Eli Lilly And Company GLP-1 formulations with protracted time action
CA2458371A1 (en) 2001-08-23 2003-03-06 Eli Lilly And Company Glucagon-like peptide-1 analogs
CA2452044A1 (en) 2001-08-28 2003-03-13 Eli Lilly And Company Pre-mixes of glp-1 and basal insulin
WO2003035099A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
SE524990C2 (sv) * 2002-04-12 2004-11-09 Microdrug Ag Preparation av terapeutiskt torrt pulver samt förfarande för uppdelning och spridning i luft av medicinskt pulver
US20040038865A1 (en) 2002-08-01 2004-02-26 Mannkind Corporation Cell transport compositions and uses thereof
JP4828940B2 (ja) * 2002-08-01 2011-11-30 マンカインド コーポレイション 細胞輸送組成物およびこれらの使用
US11304992B2 (en) * 2002-08-01 2022-04-19 Mannkind Corporation Inhalable dry powder pharmaceutical composition
US20080260838A1 (en) * 2003-08-01 2008-10-23 Mannkind Corporation Glucagon-like peptide 1 (glp-1) pharmaceutical formulations
US20040121964A1 (en) 2002-09-19 2004-06-24 Madar David J. Pharmaceutical compositions as inhibitors of dipeptidyl peptidase-IV (DPP-IV)
CA2509755A1 (en) * 2002-12-27 2004-07-22 Diobex, Inc. Compositions and methods for the prevention and control of insulin-induced hypoglycemia
EP1622633B1 (en) * 2003-05-15 2016-02-24 Ampio Pharmaceuticals, Inc. Treatment of t-cell mediated diseases
US20070027063A1 (en) * 2004-01-12 2007-02-01 Mannkind Corporation Method of preserving the function of insulin-producing cells
ATE486064T1 (de) 2004-08-20 2010-11-15 Mannkind Corp Katalyse der diketopiperazinsynthese
CN101014321A (zh) 2004-08-23 2007-08-08 曼金德公司 5型磷酸二酯酶抑制剂的肺部给予
KR20130066695A (ko) 2004-08-23 2013-06-20 맨카인드 코포레이션 약물 전달용 디케토피페라진염, 디케토모르포린염 또는 디케토디옥산염
DE102005033398A1 (de) * 2004-11-10 2006-05-11 Alfred Von Schuckmann Inhalier-Gerät
SE0402976L (sv) 2004-12-03 2006-06-04 Mederio Ag Medicinsk produkt
US20100041612A1 (en) 2005-09-08 2010-02-18 Martin Beinborn Fragments of the Glucagon-Like Peptide-1 and Uses Thereof
MX373000B (es) * 2005-09-14 2020-05-21 Mannkind Corp Metodo para formulacion de farmaco basado en el aumento de la afinidad de agentes activos hacia las superficies de microparticulas cristalinas.
US8039432B2 (en) * 2005-11-09 2011-10-18 Conjuchem, Llc Method of treatment of diabetes and/or obesity with reduced nausea side effect
CN101389648B (zh) * 2006-02-22 2013-07-17 默沙东公司 肽胃泌酸调节素衍生物
EP1986679B1 (en) * 2006-02-22 2017-10-25 MannKind Corporation A method for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
MX2008013216A (es) * 2006-04-14 2008-10-27 Mannkind Corp Formulaciones farmaceuticas de peptido-1 tipo glucagon (glp-1).
JP2010534563A (ja) * 2007-07-24 2010-11-11 ネクスバイオ,インク. マイクロ粒子の作製のための技術
JP5813323B2 (ja) * 2007-10-24 2015-11-17 マンカインド コーポレイション 活性薬剤の送達方法
EP2060268A1 (en) 2007-11-15 2009-05-20 Novo Nordisk A/S Pharmaceutical compositions for pulmonary or nasal delivery of peptides
JP2011516541A (ja) * 2008-04-07 2011-05-26 ナショナル インスティテュート オブ イミュノロジー 糖尿病および他の慢性疾患の治療に有用な組成物

Similar Documents

Publication Publication Date Title
JP2011500851A5 (https=)
RU2012136221A (ru) Доставка активных веществ
AU2018200429B2 (en) Mast Cell Stabilizers Treatment For Systemic Disorders
JP2011500850A5 (https=)
ES2775498T3 (es) Formulación en polvo nasal para el tratamiento de la hipoglucemia
JP2004522714A5 (https=)
ES2922551T3 (es) Tratamiento de pacientes con diabetes mellitus tipo 2
JP2013518124A5 (https=)
JP2020536121A5 (https=)
JP2023524064A (ja) ウイルス感染を治療又は予防するためのクロファジミン組成物及び方法
JP7369523B2 (ja) 中等度~重度のインフルエンザの処置
JP2012532852A (ja) 2型糖尿病における食後高血糖の経頬粘膜治療の方法、および当該治療に用いられる医薬組成物
Siekmeier et al. Aerosolized GLP-1 for treatment of diabetes mellitus and irritable bowel syndrome
JP2008189679A (ja) 2型糖尿病治療用の併用医薬
CN1297272C (zh) 马来酸氯苯那敏的新用途
JP2006508993A5 (https=)
Imenshahidi et al. Pulmonary delivery of insulin by dry powder inhaler formulations
Roe et al. Doctor, stop needling me: an update on alternative routes of insulin administration